单次与三次立体定向放疗治疗外周I-II期非小细胞肺癌的长期随机II期研究
这项多机构随机II期试验纳入98例不可手术的外周T1-T2/N0M0非小细胞肺癌患者,比较30 Gy单次与60 Gy分3次立体定向放疗。长期随访显示两组毒性、局部失败、远处失败、无进展生存和总生存均无差异。
要点
- 30 Gy单次与60 Gy分3次在毒性及肿瘤控制方面等效。
- 两组局部失败、远处失败、PFS和OS均无显著差异。
- 长期随访未观察到新的相关不良事件。
核心结论
- 30 Gy单次立体定向放疗在毒性、局部失败、远处失败、PFS和OS方面与60 Gy分3次等效。
研究设计与样本
- 多机构随机II期两臂临床试验,纳入98例活检证实、医学上不可手术的外周临床T1-T2/N0M0非小细胞肺癌患者,按体能状态分层随机分入30 Gy单次组或60 Gy分3次组。
主要发现
- 2008年9月至2015年4月共随机98例患者,中位生存期为40.3个月。
- 额外随访期内未出现新的归因不良事件。
关键数值与推荐
- 主要终点为根据常见不良事件评价标准(CTCAE)评估的胸部≥3级不良事件。
临床怎么用
- 对于不可手术的早期外周非小细胞肺癌,30 Gy单次立体定向放疗可作为与60 Gy分3次等效的治疗选择。
局限性
- 摘要未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy is standard of care for inoperable early-stage non-small cell lung cancer. Here, we report the long-term outcomes of 30 Gy in 1 fraction (arm 1) versus 60 Gy in 3 fractions (arm 2). METHODS AND MATERIALS: This was a multi-institutional randomized, phase 2, 2-arm clinical trial. Medically inoperable patients with peripheral clinical T1-T2/N0M0 disease were enrolled. All patients had biopsy-confirmed disease. Patients were stratified by performance status and randomized to arm 1 or arm 2. The primary endpoint was thoracic grade 3 or higher adverse events per the Common Terminology Criteria for Adverse Events. Secondary endpoints included freedom from local failure, freedom from distal failure, progression-free (PFS) and overall survival (OS). RESULTS: Between September 2008 and April 2015, 98 patients were randomized. Median survival was 40.3 months. There were no new attributable adverse events within the additional follow-up period. There were no differences in time to local failure, time to distant failure, PFS, or OS (P = .14, .17, .98, and .78, respectively). CONCLUSIONS: This randomized phase 2 study demonstrated that 30 Gy in 1 fraction was equivalent to 60 Gy in 3 fractions in terms of toxicity, local failure, distant failure, PFS, and OS.
引用
- Singh AK, Farrugia MK, Stephans KL, et al. Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41833909. doi:10.1016/j.ijrobp.2026.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。